Clancy J. Clark, MD, FACS

Liver, Bile Duct, Gallbladder and Pancreatic Surgeon in Winston-Salem, North Carolina

neoadjuvant

Alliance A021806 is a Phase III trial that aims to evaluate the efficacy of perioperative chemotherapy with mFOLFIRINOX in patients with resectable pancreatic cancer.1, 2 The study is actively accruing randomized controlled phase III trial evaluating the efficacy of perioperative chemotherapy with mFOLFIRINOX

Alliance A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer

Wake Forest Baptist Health will be joining the Alliance clinical trial A021806. This phase III that compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed